Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Serum galectin-3 predicts renal impairment in stable decompensated cirrhosis

25 Dec 2019

In patients with stable decompensated cirrhosis, galectin-3 may be an indicator of established chronic kidney disease (CKD), a recent study has shown.

Using a chemiluminescent microparticle immunoassay, researchers measured the galectin-3 levels in serum samples of 100 patients (mean age, 52±11 years; 69 percent male) with stable decompensated cirrhosis. Estimated glomerular filtration rate (eGFR), along with the 51chromium-EDTA method, was used to evaluate renal function.

The mean eGFR in the sample was 88±27 mL/mean, while the true-GFR, measured with the EDTA-based approach, was 80±27 mL/min. By the end of the study, 16 percent (n=16) had died and 14 percent (n=14) had undergone liver transplantation. The median serum galectin-3 concentration was 17.5 ng/mL.

True-GFR was significantly higher in patients with serum galectin-3 levels <11.7 ng/mL (90±20 vs 76±26 mL/min; p=0.03). The opposite was true for serum creatinine concentrations (0.83±0.14 vs 0.97±0.4 mg/dL, respectively; p=0.05). No such significant disparity was reported for eGFR. Participants were followed for a median of 14.5 months.

Researchers then divided the participants into two groups according to renal function: true-GFR ≥60 mL/min (n=76) and <60 mL/min (n=24). Serum galectin-3 levels were significantly lower in the former group (15.1 vs 24 ng/mL; p=0.01).

Multivariate analysis found that only serum galectin-3 was a significant and independent predictor of renal function (odds ratio, 0.869, 95 percent confidence interval, 0.761–0.994; p=0.04). Receiver operating characteristic curve analysis showed that at a cutoff of 17.5 ng/mL, the biomarker had good performance in predicting renal impairment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.